Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; carmellose calcium; sucralose; mannitol - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: carmellose calcium; sucralose; mannitol; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olanzapine, quantity: 20 mg - tablet, orally disintegrating - excipient ingredients: colloidal anhydrous silica; carmellose calcium; sucralose; microcrystalline cellulose; mannitol; magnesium stearate - - treatment of schizophrenia and related psychoses;. - short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder;. - preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - lacosamide, quantity: 10 mg - solution - excipient ingredients: glycerol; sodium chloride; carmellose sodium; sorbitol solution (70 per cent) (crystallising); macrogol 4000; citric acid; acesulfame potassium; sodium methyl hydroxybenzoate; purified water; flavour - vimpat (lacosamide) tablets and oral solution are indicated as:,? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.,? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.,? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - furosemide - oral solution - 4mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - furosemide - oral solution - 10mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rizatriptan benzoate, quantity: 7.265 mg (equivalent: rizatriptan, qty 5 mg) - tablet, orally disintegrating - excipient ingredients: sucralose; magnesium stearate; mannitol; crospovidone; microcrystalline cellulose; flavour - rizatriptan is indicated for the acute treatment of migraine attacks with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rizatriptan benzoate, quantity: 14.53 mg (equivalent: rizatriptan, qty 10 mg) - tablet, orally disintegrating - excipient ingredients: aspartame; crospovidone; calcium silicate; colloidal anhydrous silica; magnesium stearate; mannitol; microcrystalline cellulose; flavour - rizatriptan odt is indicated for the acute treatment of migraine attacks with or without aura.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lansoprazole, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: crospovidone; magnesium carbonate hydrate; aspartame; macrogol 6000; sodium bicarbonate; iron oxide yellow; sodium starch glycollate type a; citric acid monohydrate; hyprolose; magnesium stearate; mannitol; sodium lauryl sulfate; purified talc; iron oxide red; microcrystalline cellulose; sodium hydroxide; triethyl citrate; polysorbate 80; methacrylic acid - ethyl acrylate copolymer (1:1); sucrose; maize starch; flavour - adults,1.healing and long-term management of reflux oesophagitis. ,2.healing and long-term management for patients with duodenal ulcer. ,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. ,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). ,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. ,paediatric patients 6 to 17 years of age. ,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. ,2.healing of erosive oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lansoprazole, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: sodium bicarbonate; magnesium carbonate hydrate; sodium hydroxide; macrogol 6000; citric acid monohydrate; aspartame; crospovidone; hyprolose; sodium starch glycollate type a; magnesium stearate; mannitol; methacrylic acid - ethyl acrylate copolymer (1:1); microcrystalline cellulose; triethyl citrate; sodium lauryl sulfate; iron oxide yellow; iron oxide red; polysorbate 80; purified talc; sucrose; maize starch; flavour - adults,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.